The role of human umbilical cord tissue-derived mesenchymal stromal cells (UCX®) in the treatment of inflammatory arthritis

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Santos, Jorge M ^a   Bárcia, Rita N ^a   Simões, Sandra I ^b   Gaspar, Manuela M ^b   Calado, Susana ^b   Água Doce, Ana ^c   Almeida, Sílvia C P ^c   Almeida, Joana ^a   Filipe, Mariana ^a   Teixeira, Mariana ^a   Martins, José P ^a   Graça, Luís ^c   Cruz, Maria E M ^b   Cruz, Pedro ^a   Cruz, Helder ^a  

^a ECBio Investigação e Desenvolvimento em Biotecnologia S A   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Anti inflammatory; Arthritic inflammation; Autoimmune; Immunosuppressive; Mesenchymal stromal cells; UCX cells; Umbilical cord tissue

Indexed keywords

5' NUCLEOTIDASE; CARRAGEENAN; ENDOGLIN; HERMES ANTIGEN; THY 1 ANTIGEN;

ADIPOCYTE; ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL THERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; NONHUMAN; OSTEOBLAST; PAW EDEMA; RAT; REGULATORY T LYMPHOCYTE; REMISSION; T LYMPHOCYTE ACTIVATION; UMBILICAL CORD;

ANIMALS; ANTIGENS, CD; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; CELL DIFFERENTIATION; CELL PROLIFERATION; FLOW CYTOMETRY; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MESENCHYMAL STROMAL CELLS; RATS; RATS, WISTAR; UMBILICAL CORD;

EID: 84872268288     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-18     Document Type: Article

References (39)

1. Farheen K, Agarwal SK. Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J Manag Care Pharm 2011, 17:S09-S13.
2. van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. Ann Rheum Dis 2005, 64:537-543. 10.1136/ard.2004.024927, 1755439, 15769913.
3. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009, 11:R131. 10.1186/ar2798, 2745815, 19715572.
4. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology biologics register. Arthritis Rheum 2006, 54:1786-1794. 10.1002/art.21830, 16736520.
5. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006, 8:R66. 10.1186/ar1933, 1526636, 16600016.
6. Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lonnies L, Elgue G, Nilsson-Ekdahl K, Mougiakakos D, Lambris JD, et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One 2011, 6:e21703. 10.1371/journal.pone.0021703, 3128611, 21747949.
7. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009, 27:1421-1432. 10.1002/stem.68, 2704254, 19489103.
8. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761. 10.1182/blood-2005-04-1496, 15905186.
9. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O, Charbord P, Domenech J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007, 25:1737-1745. 10.1634/stemcells.2007-0054, 17395768.
10. Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, Kaps C, Sittinger M. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007, 101:135-146. 10.1002/jcb.21172, 17295203.
11. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 2012, 67:1-8.
12. De Miguel E, Roxo A, Castillo C, Peiteado D, Villalba A, Martin-Mola E. The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arthritis. Clin Exp Rheumatol 2012, 30:S34-S38.
13. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J, Demarquay C, Cuvelier F, Mathieu E, Trompier F, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003, 5:1028-1038. 10.1002/jgm.452, 14661178.
14. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010, 5:e9016. 10.1371/journal.pone.0009016, 2814860, 20126406.
15. Wu CC, Wu TC, Liu FL, Sytwu HK, Chang DM. TNF-alpha inhibitor reverse the effects of human umbilical cord-derived stem cells on experimental arthritis by increasing immunosuppression. Cell Immunol 2012, 273:30-40. 10.1016/j.cellimm.2011.11.009, 22196378.
16. Liu Y, Mu R, Wang S, Long L, Liu X, Li R, Sun J, Guo J, Zhang X, Yu P, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010, 12:R210. 10.1186/ar3187, 3046518, 21080925.
17. Lin W, Oh SK, Choo AB, George AJ. Activated T-cells modulate immunosuppression by embryonic- and bone marrow-derived mesenchymal stromal cells through a feedback mechanism. Cytotherapy 2012, 14:274-284. 10.3109/14653249.2011.635853, 22136295.
18. Santos J, Soares R, Martins JP, Basto V, Coelho M, Cruz P, Cruz H. Isolation method of precursor cells from human umbilical cord 2008, Portugal: Medinfar, ECBio, INPI ed., vol. 103843.
19. Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, Helwig B, Beerenstrauch M, Abou-Easa K, Hildreth T, et al. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 2003, 21:50-60. 10.1634/stemcells.21-1-50, 12529551.
20. Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, Luo Y, Rao MS, Velagaleti G, Troyer D. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of parkinson's disease. Stem Cells 2006, 24:781-792. 10.1634/stemcells.2005-0330, 16223852.
21. Cooper K, Viswanathan C. Establishment of a mesenchymal stem cell bank. Stem Cells Int 2011, 2011:905621. 3150152, 21826152.
22. Marmotti A, Mattia S, Bruzzone M, Buttiglieri S, Risso A, Bonasia DE, Blonna D, Castoldi F, Rossi R, Zanini C, et al. Minced umbilical cord fragments as a source of cells for orthopaedic tissue engineering: an in vitro study. Stem Cells Int 2012, 2012:326813. 3328184, 22550503.
23. Titushkin IA, Shin J, Cho M. A new perspective for stem-cell mechanobiology: biomechanical control of stem-cell behavior and fate. Crit Rev Biomed Eng 2010, 38:393-433. 10.1615/CritRevBiomedEng.v38.i5.10, 21175407.
24. Winter CA, Risley EA, Nuss GW. Carrageenan-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 1962, 111:544-547.
25. Simoes SI, Delgado TC, Lopes RM, Jesus S, Ferreira AA, Morais JA, Cruz ME, Corvo ML, Martins MB. Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in transfersomes. J Control Release 2005, 103:419-434. 10.1016/j.jconrel.2004.12.008, 15763624.
26. Gaspar MM, Boerman OC, Laverman P, Corvo ML, Storm G, Cruz ME. Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J Control Release 2007, 117:186-195. 10.1016/j.jconrel.2006.10.018, 17169460.
27. Taurog JD, Kerwar SS, McReynolds RA, Sandberg GP, Leary SL, Mahowald ML. Synergy between adjuvant arthritis and collagen-induced arthritis in rats. J Exp Med 1985, 162:962-978. 10.1084/jem.162.3.962, 2187796, 3161976.
28. Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 2008, 124:13-22. 10.1111/j.1365-2567.2008.02813.x, 2434375, 18346152.
29. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T-cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T-cell numbers. Arthritis Rheum 2008, 58:875-887. 10.1002/art.23291, 2675006, 18311821.
30. Graca L. New tools to identify regulatory T-cells. Eur J Immunol 2005, 35:1678-1680. 10.1002/eji.200526303, 15902689.
31. Oliveira VG, Caridade M, Paiva RS, Demengeot J, Graca L. Sub-optimal CD4+ T-cell activation triggers autonomous TGF-beta-dependent conversion to Foxp3+ regulatory T-cells. Eur J Immunol 2011, 41:1249-1255. 10.1002/eji.201040896, 21469093.
32. Duarte J, Agua-Doce A, Oliveira VG, Fonseca JE, Graca L. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One 2010, 5:e10558. 10.1371/journal.pone.0010558, 2866666, 20479941.
33. Duarte J, Carrie N, Oliveira VG, Almeida C, Agua-Doce A, Rodrigues L, Simas JP, Mars LT, Graca L. T-cell apoptosis and induction of Foxp3+ regulatory T-cells underlie the therapeutic efficacy of CD4 blockade in experimental autoimmune encephalomyelitis. J Immunol 2012, 189:1680-1688. 10.4049/jimmunol.1201269, 22802417.
34. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317. 10.1080/14653240600855905, 16923606.
35. Papadopoulou A, Yiangou M, Athanasiou E, Zogas N, Kaloyannidis P, Batsis I, Fassas A, Anagnostopoulos A, Yannaki E. Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann Rheum Dis 2012, 71:1733-1740. 10.1136/annrheumdis-2011-200985, 22586171.
36. Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, Boutarfa A, Bouchet S, Gorin NC, Thierry D, Fouillard L. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84:231-237. 10.1097/01.tp.0000267918.07906.08, 17667815.
37. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011, 6:457-478. 10.1146/annurev-pathol-011110-130230, 21073342.
38. Londei M. Role of regulatory T-cells in experimental arthritis and implications for clinical use. Arthritis Res Ther 2005, 7:118-120. 10.1186/ar1745, 1174967, 15899062.
39. Lan Q, Fan H, Quesniaux V, Ryffel B, Liu Z, Zheng SG. Induced Foxp3(+) regulatory T-cells: a potential new weapon to treat autoimmune and inflammatory diseases?. J Mol Cell Biol 2012, 4:22-28. 10.1093/jmcb/mjr039, 3491614, 22107826.